Hengrui Pharma(SH:600276) Xin Lang Zheng Quan·2025-11-26 01:54Core Viewpoint - Heng Rui Medicine's stock price has shown a significant increase this year, with a 36.06% rise, indicating strong market performance despite recent fluctuations in the short term [1] Company Overview - Jiangsu Heng Rui Medicine Co., Ltd. is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology and covering various research areas including kinase inhibitors, antibody-drug conjugates (ADC), tumor immunology, and hormone receptor regulation [2] - The company's revenue composition includes 86.88% from product sales, 12.63% from licensing income, and 0.49% from other sources [2] - Heng Rui Medicine operates in both domestic and international markets and is classified under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and preparations [2] Financial Performance - As of September 30, Heng Rui Medicine reported a revenue of 23.188 billion yuan, representing a year-on-year growth of 14.85%, and a net profit attributable to shareholders of 5.751 billion yuan, with a year-on-year increase of 24.50% [3] - The company has distributed a total of 9.303 billion yuan in dividends since its A-share listing, with 3.568 billion yuan distributed over the past three years [4] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 397,300, with an average of 16,058 circulating shares per person, a decrease of 8.21% from the previous period [3] - Major shareholders include Hong Kong Central Clearing Limited and China Securities Finance Corporation, with notable changes in their holdings [4]